Multisystem Inflammatory Syndrome In Children

Cases of multisystem inflammatory syndrome in children increased by nearly two-thirds last fall, aligning with an increase in COVID-19 activity, according to a study published in MMWR.

Children who received two or more doses of COVID-19 messenger RNA vaccine were 40% less likely to be hospitalized or visit an ED due to the disease, according to findings published in MMWR.

Hospitalized patients with multisystem inflammatory syndrome in children — or MIS-C —are far more likely to experience shock than those hospitalized with Kawasaki disease, according to a study.

A large study in the United Kingdom revealed some “epidemiologic nuances” of COVID-19 in children, experts said.

The European Alliance of Associations for Rheumatology issued updated guidance recommending weekly tocilizumab, along with glucocorticoids that should eventually be tapered, for patients with new, relapsing giant cell arteritis.

Key risk factors that may predict severe disease in patients with MIS-C include fever greater than 103.1 degrees Fahrenheit, central nervous system involvement and left ventricular dysfunction, according to data published in Rheumatology.

A study found no reported serious adverse events among children who received a COVID-19 vaccine after recovering from multisystem inflammatory syndrome in children, or MIS-C, according to results published in JAMA Network Open.

SARS-CoV-2-related neurologic effects endured among children and adolescents in the United States who were hospitalized in 2021 for COVID-19 or multisystem inflammatory syndrome, researchers reported in JAMA Neurology.

The risk for multisystem inflammatory syndrome in children after infection with SARS-CoV-2 was substantially lower during the omicron wave compared with other variants, researchers from Denmark reported in JAMA Pediatrics.

DENVER — The interleukin-1 inhibitor anakinra has little to no effect on moderate to severe multisystem inflammatory syndrome in children, according to researchers.